Abstract：Objective: To explore the change and clinical significance of serum markers in Down syndrome (Down syndrome,DS) prenatal screening. Methods: The selection from July 2014 to July 2017 in our hospital during the application of quantitative mass spectrometry was used to detect 2598 cases of 14+1~21+6weeks pregnant women were detected serum AFP、uE3、HCG and InhA markers and content, combined with maternal age, body mass, gestational weeks, single twins, smoking history, whether patients with diabetes, previous factors without abnormal pregnancy history, the use of Teng cheng version of the system risk assessment. Results: The 2598 cases of pregnant women, screening out the abnormal chromosome 117 cases of pregnant women with high risk pregnancy, including 54 cases of pregnant women were amniocentesis antenatal examination, diagnosis of Down syndrome in 21 cases, 2 cases of trisomy 18-syndrome, 3 cases of other fetal chromosomal abnormalities. (1) The levels of AFP and uE3 were lower than that in the low-risk group, [(15.54±1.23)vs.(35.38±3.54) ng/mL] and [(4.16±3.25)vs.(8.31±2.26) ng/mL] , respectively. the difference was significant (P<0.05). The levels of HCG and InhA were higher than that that in the low risk group, [(2.94±1.26)vs.(1.16±3.12) mIU/mL] and [(2.94±1.26)vs.(1.16±3.12) mIU/mL], respectively.(2) The total positive rate of screening for birth defects in the >35-year-old pregnant women (10.08%) was higher in ≤35-year-old pregnant women (3.50%), the difference was significant (P<0.05). (3) The total positive rate of diagnosis of birth defects in high-risk group (65.22%) was significantly higher than that in the low-risk pregnant women (35.48%), the difference was significant (P<0.05). (4) The levels of serum HCG and InhA rise while The levels of serum AFP and InhA reduced in the pregnant women of pregnancy DS fetal. Conclusions: The second trimester serum marker examination can be used as an important index prediction of fetal chromosomal abnormalities, and take effective measures in a timely manner through the prenatal diagnosis, can significantly reduce the birth defects, to help students work.
付久园,肖艳平,王红杰,朱艳菊,王晓华,张金环. 唐氏综合征产前血清标记物筛查的探讨[J]. 河北医学, 2017, 23(12): 2010-2012.
FU Jiuyuan, XIAO Yanping, et al. To Investigate the Serum Marker Pregnancy Detection in Prenatal Screening for Down Syndrome. HeBei Med, 2017, 23(12): 2010-2012.
[1] 蔡锦梅,黄雪珍,张瑞雄,等.唐氏综合征筛查在产前诊断的应用分析[J].实用妇科内分泌电子杂志,2016,3(20):103~104. [2] 杨小兰,陈建国,李明月,等.血清β-HCG及孕酮联合彩色B超检查对早期异常妊娠诊断价值的探讨[J].中国初级卫生保健,2014,28(4):45~47. [3] 庞春玉,吴学礼.甲胎蛋白、人绒毛膜促性腺激素及非结合雌三醇在产前筛查中的临床意义[J].临床与病理杂志,2016,36(8):1193~1197. [4] 刘艳琳,冯素娥.孕早中期1315例母血唐氏综合征产前筛查实验分析[J].实用医学杂志,2011,23(14):2204~2205. [5] 余奇松,陈萍,李敏清,等.孕中期血清标记物检测在唐氏综合征筛查及产前诊断中的意义[J].广西医科大学学报,2011,25(2):238~284. [6] 俞冬熠,温严,傅平,等.孕中期检测母血清标记物筛查唐氏综合征胎儿的研究[J],中国计划生育学杂志,2011,87(1):41~43. [7] 吴晓霞,袁晖,张育森,等.18-三体综合征胎儿母体血清学筛查及超声检查分析[J].中国优生与遗传杂志,2013,21(7):49~51. [8] Snijders RJ,Noble P,Sebire N,et al.UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation.Fetal Medicine Foundation First Trimester Screening Group[J].The Lancet,1998,352:343~346. [9] Wald NJ,Rodeck C,Hackshaw AK,et al.First and second trimester antenatal screening for Down's syndrome:the results of the Serum,Urine and Ultrasound Screening Study(SURUSS) [J].J Med Screen 2003;10(2):56~104. [10] 李彩霞.孕中期检测血清AFP、beta-HCG及uE3对唐氏综合征筛查的临床意义[J].医药论坛杂志,2014,35(12):70~72. [11] 袁晃堆.妊娠中期血清标记物检测在唐氏综合征产前筛查中的探讨[J].医学检验与临床,2015,26(2):31~33. [12] Weiss AH, Kelly JP, Phillips JO. Infantile nystagmus and abnormalities of conjugate eye movements in Down syndrome[J]. Invest Ophthalmol Vis Sci, 2016, 57(3): 1301~1309.
2017, Vol. 23 
冀公网安备13080202000677号